Widening the Aperture; New Approaches for Immunotherapy in Prostate Cancer

Session 10: Widening the Aperture; New Approaches for Immunotherapy in Prostate Cancer
Friday, November 5, 2021 | 8:50 AM – 10:35 AM PST

Moderator: Amy Moran, PhD, Oregon Health & Science University

A T Cell Intrinsic Role for Androgen Receptor Signaling and Immunotherapy Resistance
Amy Moran, PhD, Oregon Health & Science University

Checkpoint Immunotherapy in mCRPC with CDK12-Loss
Ajjai Alva, MD, University of Michigan

MGC018, an Anti-B7-H3 Antibody-Drug Conjugate (ADC), in Patients With mCRPC: Preliminary Results of Phase 1 Cohort Expansion
Chet Bohac, PharmD, MD, MSc, MacroGenics, Inc.

Targeting DLL3 with a Bi-Specific T Cell Engager: AMG 757 in De Novo and Treatment-Emergent Small Cell Neuroendocrine Prostate Cancer
Rahul Aggarwal, MD, University of California, San Francisco

Advancing the Frontiers of T-Cell Redirecting Agents in Prostate Cancer
Oliver Sartor, MD, Tulane University

82 cents of every dollar donated goes to our prostate cancer research mission

Join the fight against prostate cancer today. Donate